Short Interest in Acasti Pharma Inc. (NASDAQ:ACST) Grows By 281.3%

Acasti Pharma Inc. (NASDAQ:ACST) saw a large growth in short interest during the month of July. As of July 15th, there was short interest totalling 6,100 shares, a growth of 281.3% from the June 30th total of 1,600 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 13,200 shares, the short-interest ratio is presently 0.5 days.

Acasti Pharma Stock Performance

Shares of ACST traded up $0.06 during mid-day trading on Thursday, hitting $2.94. The company’s stock had a trading volume of 3,573 shares, compared to its average volume of 13,160. The firm has a 50-day moving average price of $2.97 and a 200 day moving average price of $2.99. Acasti Pharma has a fifty-two week low of $1.72 and a fifty-two week high of $3.59.

Acasti Pharma (NASDAQ:ACST) last announced its earnings results on Friday, June 21st. The biopharmaceutical company reported ($0.18) EPS for the quarter, topping the consensus estimate of ($0.48) by $0.30. Equities research analysts anticipate that Acasti Pharma will post -1.14 EPS for the current fiscal year.

Acasti Pharma Company Profile

Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.